Total symptom scores | Full analysis set | Per - protocol analysis set | ||||
---|---|---|---|---|---|---|
 | XBCQa | Controla | Treatment effectb | XBCQa | Controla | Treatment effectb |
 | (n = 122) | (n = 122) | (95% CI;P-value) | (n = 122) | (n = 122) | (95% CI;P- value) |
1 d | 19.70 (4.23) | 20.10 (4.28) | -0.39 (-1.47, 0.68; .471) | 19.64 (4.24) | 20.09 (4.32) | -0.45 (-1.56, 0.67; .433) |
3 d | 13.92 (4,46) | 16.48 (4.08) | -2.57 (-3.64, -1.49; < .001) | 13.82 (4.50) | 16.42 (3.95) | -2.60 (-3.70, -1.49; < .001) |
5 d | 10.64 (4.28) | 13.20 (4.18) | -2.56 (-3.63, -1.49; < .001) | 10.59 (4.24) | 13.12 (4.10) | -2.52 (-3.61, -1.44; < .001) |
7 d | 7.72 (4.34) | 9.64 (3.68) | -1.92 (-2.93, -0.90; < .001) | 7.64 (4.38) | 9.54 (3.65) | -1.90 (-2.95, -0.86; < .001) |
10 d | 5.21 (4.43) | 7.00 (3.72) | -1.79 (-2.82, -0.76; 0.001) | 5.03 (4.29) | 6.92 (3.74) | -1.89 (-2.93, -0.84; < .001) |
Meanc | 11.44 (3.36) | 13.28 (3.09) | -1.84 (-2.66, -1.03; < .001) | 11.34 (3.40) | 13.22 (3.05) | -1.87 (-2.71, -1.03; < .001) |